<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151877</url>
  </required_header>
  <id_info>
    <org_study_id>K5900209</org_study_id>
    <nct_id>NCT02151877</nct_id>
  </id_info>
  <brief_title>Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass</brief_title>
  <official_title>Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chawki Elzein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Advocate Health Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Around 7500 neonates born yearly in the United States have complex congenital heart disease
      that require surgical repair in the first few days of life. The complexity of the surgical
      repair requires long periods of cardiopulmonary bypass (CPB) and the use of intermittent
      periods of low flow or complete circulatory arrest. The immature neonatal vital organs are
      more prone to the complications of the cardiopulmonary bypass circulation, namely
      ischemia/reperfusion (I/R) injury and systemic inflammatory response. Inhaled nitric oxide
      (NO) is used frequently in neonates for the treatment of pulmonary hypertension,
      Additionally, many studies have shown that NO has an anti-inflammatory effect by reducing I/R
      injury and endothelial dysfunction.

      The purpose of this pilot study is to assess the efficacy of NO administration via the CPB
      circuit in attenuating the CPB induced I/R injury and systemic inflammatory reaction in
      neonates undergoing repair of complex congenital heart defects. Specific goals will be to
      demonstrate that NO use via CPB will:

        -  Decrease markers of I/R injury and systemic inflammatory response.

        -  Decrease platelet activation leading to reduced postoperative bleeding and transfusion
           requirements.

        -  Decrease postoperative organ dysfunction, and hence decrease operative mortality and
           postoperative morbidity.

      Twelve neonates undergoing repair of complex congenital heart defects will receive NO via the
      CPB circuit, for the duration of surgery. They will be compared to a control group of 12
      similar patients. Serum levels of different ischemic reperfusion injury and inflammatory
      markers will be measured at different time points after surgery and will be correlated with
      different end organ function tests and clinical course in the postoperative period. The
      results will be compared between the two groups to try to determine the clinical benefit of
      NO administration through CPB circuit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Biochemical Markers of Ischemia/Reperfusion Injury and Oxidative Damage (Positive ~ Increase From Pre-op)</measure>
    <time_frame>Pre-op baseline and up to 12 hours after surgery</time_frame>
    <description>The primary study endpoints are to evaluate whether NO delivered through the neonatal cardiopulmonary bypass (CPB) circuit can decrease various biochemical markers of ischemia/reperfusion injury and oxidative damage. Markers to be analyzed will include cardiac troponin I, interleukins (IL), tumor necrosis factor, N-terminal prohormone for brain natriuretic peptide (NT-proBNP),lactate dehydrogenase (LDH), plasma anti-oxidant levels, plasma malondialdehyde (MDA) levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Fluid Balance at 48 Hours</measure>
    <time_frame>48 hours post surgery</time_frame>
    <description>The secondary study endpoints are to evaluate whether NO delivered through the neonatal CPB circuit can decrease the clinical signs of ischemia/reperfusion injury and/or cardiac dysfunction. Clinical parameters (post surgery) include inotropic support, fluid balances, diuretic support, ventilator times, and length of ICU stay will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Until Start of Diuretic Therapy</measure>
    <time_frame>Pre-op to 72 hours post surgery</time_frame>
    <description>hours until start of diuretic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropic Score Day 1</measure>
    <time_frame>24 hours post surgery</time_frame>
    <description>The Inotropic Score is an objective clinical tool used to quantify the need for cardiovascular support in children and adolescents after surgery and to predict prognosis of pediatric septic shock (higher score predicts higher risk or worse prognosis).The Inotropic Score is low if &lt;= 20, intermediate if 21-30, and high if &gt; 30.
Formula used in the study:
Daily inotropic score (mcg/kg/min) = Dopamine drip dose+ dobutamine drip dose+ (milrinone drip dose times 10) + (epinephrine drip dose times 100 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intubation and PSHU Stay</measure>
    <time_frame>Surgery to discharge</time_frame>
    <description>Days to extubation and Pediatric Surgical Heart Unit (PSHU) length of stay (LOS) as measuring patient surgical outcomes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Surgical Morbidity</measure>
    <time_frame>1 month after cardiac surgery</time_frame>
    <description>include all complications that may happen after cardiac surgery for the whole period of hospital stay, that is expected to be around 1 month. This include renal failure, prolonged intubation and ventilatory support, infections..</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery</condition>
  <condition>Inflammatory Reaction After Neonatal Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Nitric oxide on CPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>neonates not receiving inhaled NO into the cardiopulmonary bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Nitric Oxide</intervention_name>
    <description>delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery</description>
    <arm_group_label>Nitric oxide on CPB</arm_group_label>
    <other_name>study group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates, age 0-30 days

          -  Full term, &gt; 37 weeks gestation

          -  Birth weight â‰¥ 2.6 kg

        Exclusion Criteria:

          -  Preoperative sepsis

          -  Preoperative renal dysfunction

          -  Preoperative intracranial hemorrhage

          -  Chromosomal abnormalities and/or genetic syndromes

          -  Prior intervention (catheter based or surgical)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chawki F Elzein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advocate Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advocate Children's Hospital</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.advocatechildrenshospital.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <results_first_submitted>October 30, 2019</results_first_submitted>
  <results_first_submitted_qc>April 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2020</results_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Advocate Health Care</investigator_affiliation>
    <investigator_full_name>Chawki Elzein</investigator_full_name>
    <investigator_title>Associate clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Ischemia/reperfusion injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02151877/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nitric Oxide on CPB</title>
          <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nitric Oxide on CPB</title>
          <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.67" spread="1.87"/>
                    <measurement group_id="B2" value="5.92" spread="1.78"/>
                    <measurement group_id="B3" value="5.79" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>anatomical diagnosis, hypoplastic left heart syndrome</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Biochemical Markers of Ischemia/Reperfusion Injury and Oxidative Damage (Positive ~ Increase From Pre-op)</title>
        <description>The primary study endpoints are to evaluate whether NO delivered through the neonatal cardiopulmonary bypass (CPB) circuit can decrease various biochemical markers of ischemia/reperfusion injury and oxidative damage. Markers to be analyzed will include cardiac troponin I, interleukins (IL), tumor necrosis factor, N-terminal prohormone for brain natriuretic peptide (NT-proBNP),lactate dehydrogenase (LDH), plasma anti-oxidant levels, plasma malondialdehyde (MDA) levels.</description>
        <time_frame>Pre-op baseline and up to 12 hours after surgery</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide on CPB</title>
            <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemical Markers of Ischemia/Reperfusion Injury and Oxidative Damage (Positive ~ Increase From Pre-op)</title>
          <description>The primary study endpoints are to evaluate whether NO delivered through the neonatal cardiopulmonary bypass (CPB) circuit can decrease various biochemical markers of ischemia/reperfusion injury and oxidative damage. Markers to be analyzed will include cardiac troponin I, interleukins (IL), tumor necrosis factor, N-terminal prohormone for brain natriuretic peptide (NT-proBNP),lactate dehydrogenase (LDH), plasma anti-oxidant levels, plasma malondialdehyde (MDA) levels.</description>
          <population>Intent to treat (ITT)</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cardiac troponin I change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.55"/>
                    <measurement group_id="O2" value="0.64" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.52" spread="12.98"/>
                    <measurement group_id="O2" value="26.98" spread="27.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.36" spread="42.86"/>
                    <measurement group_id="O2" value="68.46" spread="81.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.20"/>
                    <measurement group_id="O2" value="-0.12" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT pro-BNP change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="22.84"/>
                    <measurement group_id="O2" value="1.51" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.85" spread="117.39"/>
                    <measurement group_id="O2" value="53.44" spread="73.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superoxide Dismutase change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.04"/>
                    <measurement group_id="O2" value="-0.05" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma MDA change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="12.90"/>
                    <measurement group_id="O2" value="10.65" spread="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null: mean cardiac troponin I changes in the NO group = mean cardiac troponin I changes in the control</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>This test applies to the first marker, cardiac troponin I.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fluid Balance at 48 Hours</title>
        <description>The secondary study endpoints are to evaluate whether NO delivered through the neonatal CPB circuit can decrease the clinical signs of ischemia/reperfusion injury and/or cardiac dysfunction. Clinical parameters (post surgery) include inotropic support, fluid balances, diuretic support, ventilator times, and length of ICU stay will be evaluated.</description>
        <time_frame>48 hours post surgery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide on CPB</title>
            <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fluid Balance at 48 Hours</title>
          <description>The secondary study endpoints are to evaluate whether NO delivered through the neonatal CPB circuit can decrease the clinical signs of ischemia/reperfusion injury and/or cardiac dysfunction. Clinical parameters (post surgery) include inotropic support, fluid balances, diuretic support, ventilator times, and length of ICU stay will be evaluated.</description>
          <population>Intent to treat</population>
          <units>ml/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.24" lower_limit="-52.90" upper_limit="165.26"/>
                    <measurement group_id="O2" value="15.93" lower_limit="-160.55" upper_limit="73.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null: NO group fluid balances are the same as the control</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Until Start of Diuretic Therapy</title>
        <description>hours until start of diuretic therapy</description>
        <time_frame>Pre-op to 72 hours post surgery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide on CPB</title>
            <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until Start of Diuretic Therapy</title>
          <description>hours until start of diuretic therapy</description>
          <population>Intent to treat</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="22.5" upper_limit="30.25"/>
                    <measurement group_id="O2" value="21.5" lower_limit="19.25" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inotropic Score Day 1</title>
        <description>The Inotropic Score is an objective clinical tool used to quantify the need for cardiovascular support in children and adolescents after surgery and to predict prognosis of pediatric septic shock (higher score predicts higher risk or worse prognosis).The Inotropic Score is low if &lt;= 20, intermediate if 21-30, and high if &gt; 30.
Formula used in the study:
Daily inotropic score (mcg/kg/min) = Dopamine drip dose+ dobutamine drip dose+ (milrinone drip dose times 10) + (epinephrine drip dose times 100 )</description>
        <time_frame>24 hours post surgery</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide on CPB</title>
            <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
        </group_list>
        <measure>
          <title>Inotropic Score Day 1</title>
          <description>The Inotropic Score is an objective clinical tool used to quantify the need for cardiovascular support in children and adolescents after surgery and to predict prognosis of pediatric septic shock (higher score predicts higher risk or worse prognosis).The Inotropic Score is low if &lt;= 20, intermediate if 21-30, and high if &gt; 30.
Formula used in the study:
Daily inotropic score (mcg/kg/min) = Dopamine drip dose+ dobutamine drip dose+ (milrinone drip dose times 10) + (epinephrine drip dose times 100 )</description>
          <population>ITT</population>
          <units>mcg/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.75" upper_limit="19.75"/>
                    <measurement group_id="O2" value="15" lower_limit="13.5" upper_limit="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intubation and PSHU Stay</title>
        <description>Days to extubation and Pediatric Surgical Heart Unit (PSHU) length of stay (LOS) as measuring patient surgical outcomes.</description>
        <time_frame>Surgery to discharge</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide on CPB</title>
            <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intubation and PSHU Stay</title>
          <description>Days to extubation and Pediatric Surgical Heart Unit (PSHU) length of stay (LOS) as measuring patient surgical outcomes.</description>
          <population>ITT</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days to extubation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="6.25" upper_limit="9.5"/>
                    <measurement group_id="O2" value="6.5" lower_limit="5.25" upper_limit="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSHU Length of Stay (LOS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10.5" upper_limit="22.25"/>
                    <measurement group_id="O2" value="12" lower_limit="11" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Surgical Morbidity</title>
        <description>include all complications that may happen after cardiac surgery for the whole period of hospital stay, that is expected to be around 1 month. This include renal failure, prolonged intubation and ventilatory support, infections..</description>
        <time_frame>1 month after cardiac surgery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide on CPB</title>
            <description>neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
Inhaled Nitric Oxide: delivered inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>neonates not receiving inhaled NO into the cardiopulmonary bypass
placebo: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
12 patients were enrolled prospectively over 4 years period</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Morbidity</title>
          <description>include all complications that may happen after cardiac surgery for the whole period of hospital stay, that is expected to be around 1 month. This include renal failure, prolonged intubation and ventilatory support, infections..</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the entire hospitalization period, from surgical date to 104 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nitric Oxide on CPB</title>
          <description>Group that received nitric oxide in CPB</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Group that did not receive nitric oxide in CPB</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Chylothorax</sub_title>
                <description>chylothorax</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>needed cath intervention</sub_title>
                <description>developed narrowing at the proximal anastomosis of the Sano shunt, necessitating cardiac cath and stent implantation at the proximal Sano shunt</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chawki Elzein, MD, FACS</name_or_title>
      <organization>Advocate Health Care</organization>
      <phone>7086843029</phone>
      <email>chawki.elzein@advocatehealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

